ArticleJournal of the Royal Society, Interface2023
Estimating the fitness cost and benefit of antimicrobial resistance from pathogen genomic data.
Article in Journal of the Royal Society, Interface, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Quantifying the predictability of evolution by analysis of coalescent rate variation.Molecular biology and evolution · 2026Article
- Rapid growth phenotype of carbapenem-resistant Enterobacter cloacae: growth fitness, stability, and mechanistic insights.BMC genomics · 2026Article
- Quantifying the real-world impact of antibiotic use and genetic determinants of resistance on gonococcal dynamics.Nature microbiology · 2026Article
- Fitness costs and persistence of plasmid-mediated cephalosporin resistance inFrontiers in microbiology · 2026Review
- Higher levels of antibiotic resistance are less competitive: the hidden ecological cost of no-metabolic cost resistance.bioRxiv : the preprint server for biology · 2025Article
- Comparative analysis of colonization and survival strategies of regionally predominant LA-MRSA clones ST398 and ST9.mSystems · 2025Article
- Quantifying the effects of antibiotic resistance and within-host competition on strain fitness in Streptococcus pneumoniae.PLoS biology · 2025Article
- Oral and parenteral treatment with a third-generation cephalosporin promotes the proliferation of diverse ESBL-producingmSphere · 2025Article
- Coevolutionary history of predation constrains the evolvability of antibiotic resistance in prey bacteria.npj antimicrobials and resistance · 2025Article
- Avian-specificeLife · 2025Article
- Heterogeneous subpopulations inFrontiers in cellular and infection microbiology · 2025Article
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Bayesian Calibration to Address the Challenge of Antimicrobial Resistance: A Review.IEEE access : practical innovations, open solutions · 2024Article
- Estimating the fitness cost and benefit of antimicrobial resistance from pathogen genomic data.Journal of the Royal Society, Interface · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Increasing levels of antibiotic resistance in many bacterial pathogen populations are a major threat to public health. Resistance to an antibiotic provides a fitness benefit when the bacteria are exposed to this antibiotic, but resistance also often comes at a cost to the resistant pathogen relative to susceptible counterparts. We lack a good understanding of these benefits and costs of resistance for many bacterial pathogens and antibiotics, but estimating them could lead to better use of antibiotics in a way that reduces or prevents the spread of resistance. Here, we propose a new model for the joint epidemiology of susceptible and resistant variants, which includes explicit parameters for the cost and benefit of resistance. We show how Bayesian inference can be performed under this model using phylogenetic data from susceptible and resistant lineages and that by combining data from both we are able to disentangle and estimate the resistance cost and benefit parameters separately. We applied our inferential methodology to several simulated datasets to demonstrate good scalability and accuracy. We analysed a dataset of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.